Literature DB >> 36245019

Simulation study comparing analytical methods for single-item longitudinal patient-reported outcomes data.

Vinicius F Calsavara1, Márcio A Diniz2, Mourad Tighiouart2, Patricia A Ganz3, N Lynn Henry4, Ron D Hays5, Greg Yothers6, André Rogatko2.   

Abstract

PURPOSE: Efficient analytical methods are necessary to make reproducible inferences on single-item longitudinal ordinal patient-reported outcome (PRO) data. A thorough simulation study was performed to compare the performance of the semiparametric probabilistic index models (PIM) with a longitudinal analysis using parametric cumulative logit mixed models (CLMM).
METHODS: In the setting of a control and intervention arm, we compared the power of the PIM and CLMM to detect differences in PRO adverse event (AE) between these groups using several existing and novel summary scores of PROs. For each scenario, PRO data were simulated using copula multinomial models. Comparisons were also exemplified using clinical trial data.
RESULTS: On average, CLMM provided substantially greater power than the PIM to detect differences in PRO-AEs between the groups when the baseline-adjusted method was used, and a small advantage in power when using the baseline symptom as a covariate.
CONCLUSION: Although the CLMM showed the best performance among analytical methods, it relies on assumptions difficult to verify and that might not be fulfilled in the real world, therefore our recommendation is the use of PIM models with baseline symptom as a covariate.
© 2022. The Author(s).

Entities:  

Keywords:  Adverse event; Cumulative logit mixed model; PRO-CTCAE; Patient-reported outcome; Probabilistic index model; Type I and II errors

Year:  2022        PMID: 36245019     DOI: 10.1007/s11136-022-03267-z

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  21 in total

1.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Authors:  Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

2.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Authors:  Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2014-09-29       Impact factor: 13.506

3.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

Authors:  C S Cleeland; T R Mendoza; X S Wang; C Chou; M T Harle; M Morrissey; M C Engstrom
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

4.  Toxicity Index, Patient-Reported Outcomes, and Early Discontinuation of Endocrine Therapy for Breast Cancer Risk Reduction in NRG Oncology/NSABP B-35.

Authors:  N Lynn Henry; Sungjin Kim; Ron D Hays; Marcio A Diniz; Michael Luu; Reena S Cecchini; Greg Yothers; André Rogatko; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2021-09-23       Impact factor: 50.717

5.  Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Authors:  André Rogatko; James S Babb; Hao Wang; Michael J Slifker; Gary R Hudes
Journal:  Clin Cancer Res       Date:  2004-07-15       Impact factor: 12.531

6.  The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years.

Authors:  David Cella; Susan Yount; Nan Rothrock; Richard Gershon; Karon Cook; Bryce Reeve; Deborah Ader; James F Fries; Bonnie Bruce; Mattias Rose
Journal:  Med Care       Date:  2007-05       Impact factor: 2.983

7.  Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.

Authors:  Ethan Basch; Lauren J Rogak; Amylou C Dueck
Journal:  Clin Ther       Date:  2016-04-02       Impact factor: 3.393

8.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Authors:  David J Adelstein; Yi Li; George L Adams; Henry Wagner; Julie A Kish; John F Ensley; David E Schuller; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

9.  Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index.

Authors:  Gillian Gresham; Márcio A Diniz; Zahra S Razaee; Michael Luu; Sungjin Kim; Ron D Hays; Steven Piantadosi; Mourad Tighiouart; Greg Yothers; Patricia A Ganz; André Rogatko
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.